{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:03:27Z","timestamp":1793113407838,"version":"4.5.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T00:00:00Z","timestamp":1391040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0087548","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T22:23:55Z","timestamp":1391120635000},"page":"e87548","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":74,"title":["Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes"],"prefix":"10.1371","volume":"9","author":[{"given":"Eve-Irene","family":"Lepist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"St. Claire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian S.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,1,30]]},"reference":[{"key":"ref1","first-page":"1573","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc","volume":"53","author":"VV McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"M Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"DJ Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000159015","article-title":"Endothelin-1-like immunoreactivity in postobstructive pulmonary vasculopathy","volume":"30","author":"A Giaid","year":"1993","journal-title":"J Vasc Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0031-6997(25)06809-7","article-title":"Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology","volume":"46","author":"GM Rubanyi","year":"1994","journal-title":"Pharmacol Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"RN Channick","year":"2001","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"LJ Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"VV McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"RJ Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"DB Badesch","year":"2007","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"N Galie","year":"2008","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"RJ Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension","volume":"30","author":"M Humbert","year":"2007","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00194810","article-title":"Liver toxicity of sitaxentan in pulmonary arterial hypertension","volume":"37","author":"N Galie","year":"2011","journal-title":"Eur Respir J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1097\/00005344-199526003-00080","article-title":"ETA receptors predominate in the human vasculature and mediate constriction","volume":"26","author":"AP Davenport","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.lfs.2012.02.003","article-title":"Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice","volume":"91","author":"L Ling","year":"2012","journal-title":"Life Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1026A","DOI":"10.1378\/chest.1456207","article-title":"Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial (Abstract)","volume":"142","author":"LJ Rubin","year":"2012","journal-title":"Chest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","article-title":"Macitentan: entry-into-humans study with a new endothelin receptor antagonist","volume":"67","author":"PN Sidharta","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"ref19","unstructured":"Actelion Pharmaceuticals US, Inc. (2013) Opsumit (macitentan). United States Food and Drug Administration Drug Product Label 2013."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"K Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1073\/pnas.98.4.2011","article-title":"Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis","volume":"98","author":"R Wang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.hep.2003.09.037","article-title":"Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein","volume":"38","author":"R Wang","year":"2003","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/toxsci\/kfi020","article-title":"Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes","volume":"83","author":"DC Kemp","year":"2005","journal-title":"Toxicol Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"12598","DOI":"10.1021\/bi050943e","article-title":"Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice","volume":"44","author":"P Lam","year":"2005","journal-title":"Biochemistry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa0901075","article-title":"Recurrence of bile salt export pump deficiency after liver transplantation","volume":"361","author":"P Jara","year":"2009","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","article-title":"Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development","volume":"118","author":"RE Morgan","year":"2010","journal-title":"Toxicol Sci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0168-8278(02)00107-1","article-title":"Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan","volume":"37","author":"L Fouassier","year":"2002","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/bdd.527","article-title":"Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2","volume":"28","author":"Y Mano","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1139\/Y10-060","article-title":"Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes","volume":"88","author":"JC Hartman","year":"2010","journal-title":"Can J Physiol Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, <etal>et al<\/etal>. (2013) A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development. Toxicol Sci.","DOI":"10.1093\/toxsci\/kft176"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/3034","article-title":"A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis","volume":"20","author":"SS Strautnieks","year":"1998","journal-title":"Nat Genet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0016-5085(99)70287-8","article-title":"Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis","volume":"117","author":"PL Jansen","year":"1999","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1053\/j.gastro.2008.01.038","article-title":"Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families","volume":"134","author":"SS Strautnieks","year":"2008","journal-title":"Gastroenterology"},{"key":"ref34","first-page":"G12","article-title":"Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration","volume":"277","author":"X Liu","year":"1999","journal-title":"Am J Physiol"},{"key":"ref35","unstructured":"Ray A, Tong L, Brouwer K, Melvin L, Hartman JC (2009) Inhibitory Effects of ERAs on Human and Rat Hepatic Transporters. ET-11: APS International Conference on Endothelin September 9\u201312, 2009, Montr\u00e9al, Canada 16.15 (Abstract)."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","article-title":"Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist","volume":"14","author":"S Bruderer","year":"2012","journal-title":"AAPS J"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","article-title":"The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver","volume":"273","author":"T Gerloff","year":"1998","journal-title":"J Biol Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/jpet.105.084830","article-title":"Bile salt export pump (BSEP\/ABCB11) can transport a nonbile acid substrate, pravastatin","volume":"314","author":"M Hirano","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/14740338.6.1.71","article-title":"Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump","volume":"6","author":"A Sakurai","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/00007890-199706150-00006","article-title":"Cholestatic effects of cyclosporine in the rat","volume":"63","author":"FK Chan","year":"1997","journal-title":"Transplantation"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/S0041-1345(99)00554-0","article-title":"Cyclosporine inhibits transport of bile acid in rats: comparison of bile acid composition between liver and bile","volume":"31","author":"K Mizuta","year":"1999","journal-title":"Transplant Proc"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/mol.59.3.627","article-title":"Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat","volume":"59","author":"C Funk","year":"2001","journal-title":"Mol Pharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/toxsci\/kfg217","article-title":"Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats","volume":"76","author":"VE Kostrubsky","year":"2003","journal-title":"Toxicol Sci"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/dmd.109.028407","article-title":"An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes","volume":"38","author":"JH Ansede","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2013.01.010","article-title":"Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro","volume":"701","author":"J Weiss","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1593\/tlo.11286","article-title":"Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist","volume":"5","author":"SJ Kim","year":"2012","journal-title":"Transl Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/jpet.103.061614","article-title":"Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat","volume":"308","author":"A Treiber","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"A Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.clpt.6100075","article-title":"Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects","volume":"81","author":"PL van Giersbergen","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0087548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T18:27:15Z","timestamp":1746124035000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0087548"}},"subtitle":[],"editor":[{"given":"Hendrik W.","family":"van Veen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0087548","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,30]]}}}